A Phase 1 Study to Evaluate the Effect of Itraconazole on the Pharmacokinetics of GS-5718 and to Evaluate the Effect of GS-5718 on the Pharmacokinetics of Rosuvastatin in Healthy Subjects

This is a drug interaction study in healthy volunteers, testing how the investigational compound GS-5718 — a drug candidate being developed by Gilead Sciences — behaves in the body when taken alongside other medications. Specifically, the study looks at whether itraconazole (an antifungal drug that inhibits certain liver enzymes) changes how much GS-5718 gets into the bloodstream, and whether GS-5718 itself affects the levels of rosuvastatin (a cholesterol-lowering drug) in the body. Understanding these drug interactions is a critical part of making sure a new medication is safe to use in patients who might be taking other drugs at the same time. This type of pharmacokinetics study involves carefully timed blood samples after doses of each drug. You may be eligible if you are a healthy adult between 18 and 45 with a BMI between 19 and 30, are a non-smoker (and have not used nicotine for at least 90 days), and have not participated in another drug study within the past 30 days. Pregnant or breastfeeding women, people with substance use issues, and men planning to donate sperm during the study are not eligible.